Clinical Trials Arena on MSN
Imunon’s IL-12 gene therapy changes “cold” tumour microenvironment to “hot”
Translational results bolster confidence as Phase III trial for IMNN-001 in advance epithelial ovarian cancer gets underway.
Data support advancement of GS-6791 into clinical testing in patients with inflammatory diseases; first-in-human Phase 1 trial in healthy ...
Coya Therapeutics Inc. (NASDAQ:COYA) on Tuesday announced results from a study designed to evaluate the effects of COYA 303 ...
New research uncovers how cancer-induced nerve injury drives resistance to anti-PD-1 therapy, revealing potential strategies to enhance treatment efficacy.
MedPage Today on MSN
Once-Daily Pill for Psoriasis Gets High Marks in Multiple Studies
Icotrokinra is a first-in-class oral peptide drug that selectively inhibits the IL-23 receptor, disrupting IL-23 signaling ...
The use of interleukin-2 (IL-2)-directed therapies has been associated with systemic toxicities, regulatory T cell (Treg) activation and limited efficacy so far. Researchers from Regeneron ...
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback